Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Diamond

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Blood Cancer Discovery|January 4, 2024
Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer TherapiesAndrew Kowalski, Jill Lykon, Benjamin Diamond, et al.
Pathology|March 6, 2021
Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useKylee H Maclachlan, Neil Came, Benjamin Diamond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Impact of Rare Structural Variant Events in Newly Diagnosed Multiple MyelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Impact of rare structural variant events in newly diagnosed multiple myelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Blood Cancer Journal|July 19, 2024
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Blood Cancer Discovery|January 4, 2024
Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer TherapiesAndrew Kowalski, Jill Lykon, Benjamin Diamond, et al.
Pathology|March 6, 2021
Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useKylee H Maclachlan, Neil Came, Benjamin Diamond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Impact of Rare Structural Variant Events in Newly Diagnosed Multiple MyelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Impact of rare structural variant events in newly diagnosed multiple myelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Blood Cancer Journal|July 19, 2024
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Pageof 5